Tetra Bio-Pharma Inc. is developing cannabinoid-derived medicines using scientific validation and safety data that meet the requirements of the pharmaceutical industry.
The efficacy and safety of these new cannabinoid-derived drugs are tested in clinical trials before being approved by the regulatory authorities as safe and effective treatments for patients.
Tetra Bio-Pharma Inc. is developing cannabinoid-derived medicines to treat different pain conditions. Below you will find information about the completed and ongoing trials.
- Ascending Doses of PPP001 administered by smoking in healthy volunteers
This study enrolled healthy subjects and investigated the innocuity, tolerability, and pharmacokinetic profile of PPP001 when inhaled by smoking following single and multiple dosing. In addition, PPP001’s impact on cognition was measured with cognitive tests throughout the treatment.
- Single inhaled dose of PPP001 administered by vaporizing in healthy volunteers
This study enrolled healthy subjects and investigated the safety, tolerability, and pharmacokinetic profile of PPP001 when inhaled by vaporization following single dosing.
This phase 2 study is conducted in the U.S.A. and will verify the efficacy and safety of a new inhale cannabis-based drug to treat cancer-related pain in advanced cancer patients.
If you are participating in a clinical trial PLENITUDE sponsored by Tetra Bio-Pharma Inc., you will use a MIGHTY® MEDIC device. These instructional videos will show you how to use and clean your MIGHTY® MEDIC device: